US EditionRein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
- Zymeworks presented new preclinical data for its bispecific molecule ZW1528 at the American Thoracic Society International Conference on May 19, 2025, in San Francisco.
- This presentation highlighted Zymeworks' focused R&D initiative targeting autoimmune and inflammatory conditions, aiming to harness multispecific antibody technology for challenging respiratory diseases.
- ZW1528 exhibited strong binding affinity to IL-4Rα and IL-33, effectively inhibiting the signaling pathways of IL-4, IL-13, and IL-33, while also showing favorable manufacturability features such as stability at concentrations of 150 mg/mL and suitability for potential subcutaneous delivery.
- Pharmacokinetic profiles were improved in both rodent and primate preclinical studies through Fc region modifications aimed at extending half-life, with Zymeworks planning to initiate Phase 1 regulatory submissions in the latter half of 2026.
- These findings support Zymeworks' aim to improve treatment options for respiratory inflammatory diseases like COPD and advance their pipeline of novel biotherapeutics targeting difficult-to-treat conditions.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
All
Left
8
Center
1
Right
1
Inside Halton+10 Reposted by 10 other sources
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel bispecific design shows promising potential manufacturability and stability to support high dosing concentration and subcutaneous administrationRegulatory…
·Halton Hills, Canada
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left8Leaning Right1Center1Last UpdatedBias Distribution80% Left
Bias Distribution
- 80% of the sources lean Left
80% Left
L 80%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
